

# SAMORITA HOSPITAL LIMITED

## Third Quarter Financial Statements

Dear Shareholders,

We are pleased to forward herewith the unaudited Financial Statements of the company for the third quarter ended 31st March, 2022 as per Bangladesh Securities and Exchange Commission's notification No. SEC/CMRRCD/2008-183/Admin/03-34 dated September 27, 2009.

### Statement of Financial Position (Un-audited) As at 31 March, 2022 (Figure in Taka "000")

Particular	Notes	March, 31 2022	June, 30 2021
<b>Assets</b>			
<b>Non-Current Assets</b>			
Property, Plant & Equipment(WDV)	3	956,915	945,290
Investment in Associate	4	5,822	5,794
<b>Total Non-Current Assets</b>		<b>962,737</b>	<b>951,084</b>
<b>Current Assets:</b>			
Inventories	5	20,730	20,452
Accounts Receivable	6	12,578	10,430
Advance, Deposits & Prepayments	7	24,629	19,789
Advance Income Tax	8	18,070	17,743
Short-term investment in FDR	9	40,000	40,000
Cash & Cash Equivalents	10	51,367	67,308
<b>Total Current Assets</b>		<b>167,374</b>	<b>175,722</b>
<b>Total Assets</b>		<b>1,130,111</b>	<b>1,126,806</b>
<b>Equity and Liabilities</b>			
<b>Shareholders' Equity:</b>			
Share Capital	11	188,752	188,752
Retained Earnings	12	148,789	145,705
Revaluation Reserve	13	636,826	636,826
Dividend Equalisation Fund	14	2,104	-
<b>Total Equity</b>		<b>976,471</b>	<b>971,283</b>
<b>Non-Current Liabilities :</b>			
Deferred Tax Liabilities	15	39,383	40,433
Long Term Borrowings	16	39,445	51,239
<b>Total Non-Current Liabilities</b>		<b>78,828</b>	<b>91,672</b>
<b>Current Liabilities :</b>			
Accounts Payable	17	25,290	24,545
Long Term Borrowings (Current Portion)	18	21,060	5,265
Other Payable	19	2,071	1,186
Provision & Accruals	20	11,062	9,614
Liability for Income Tax	21	14,156	13,948
Unclaimed Dividend	22	1,172	9,293
<b>Total Current Liabilities</b>		<b>74,812</b>	<b>63,851</b>
<b>Total Liabilities</b>		<b>153,640</b>	<b>155,523</b>
<b>Total Equity and Liabilities</b>		<b>1,130,111</b>	<b>1,126,806</b>

### Statement of Profit or Loss and Other Comprehensive Income (Un-audited) For the third quarter ended 31st March, 2022. (Figure in Taka "000")

	Notes	July, 2021 to March, 2022	July, 2020 to March, 2021	January, 2022 to March, 2022	January, 2021 to March, 2021
Revenue	24	274,070	299,190	73,288	84,708
Direct Expenses	25	(113,281)	(124,223)	(29,795)	(35,670)
<b>Gross Profit</b>		<b>160,789</b>	<b>174,967</b>	<b>43,493</b>	<b>49,038</b>
<b>Operating Expenses:</b>					
Administrative Expenses	26	(130,100)	(135,559)	(43,690)	(44,246)
<b>Profit from Operation</b>		<b>30,689</b>	<b>39,408</b>	<b>(197)</b>	<b>4,792</b>
Share of Profit/ (loss) of Associate	23	28	61	(34)	8
Financial Expenses		(4,001)	(248)	(1,332)	(248)
<b>Non Operating Income</b>	27	<b>5,878</b>	<b>4,914</b>	<b>1,827</b>	<b>1,440</b>
<b>Profit before contribution to WPPF</b>		<b>32,594</b>	<b>44,135</b>	<b>264</b>	<b>5,992</b>
Contribution to WPPF		(1,552)	(2,102)	(13)	(285)
<b>Profit Before Tax</b>		<b>31,041</b>	<b>42,034</b>	<b>251</b>	<b>5,707</b>
<b>Income Tax Expenses</b>		<b>(6,978)</b>	<b>(12,206)</b>	<b>(64)</b>	<b>(1,424)</b>
Current Tax	28	8,028	10,927	405	1,277
Deferred Tax	15.01	(1,050)	1,280	(341)	148
<b>Profit after Tax</b>		<b>24,063</b>	<b>29,827</b>	<b>187</b>	<b>4,283</b>
<b>Total Comprehensive income</b>		<b>24,063</b>	<b>29,827</b>	<b>187</b>	<b>4,283</b>
<b>EPS</b>		<b>1.27</b>	<b>1.58</b>	<b>0.01</b>	<b>0.23</b>

  
CFO

  
Company Secretary

  
Managing Director

  
Director

  
Chairman

**Statement of Changes In Equity (Un-audited)**  
For the third quarter ended 31st March , 2022. ( Figure in Taka "000")

Particular	Share Capital	Retained Earning	Dividend Equalisation Fund	Revaluation Reserve	Total
Balance as at July 01,2021	188,752	145,705	-	636,826	971,283
Transferred to Dividend Equalisation Fund	-	(2,104)	2,104	-	-
Dividend	-	(18,875)	-	-	(18,875)
Total Comprehensive income	-	24,063	-	-	24,063
Balance as at March 2022	188,752	148,789	2,104	636,826	976,471
Balance as at July 01,2020	188,752	103,617	-	636,826	929,195
Total Comprehensive income	-	29,827	-	-	29,827
Balance as at March,2021	188,752	133,444	-	636,826	959,022

**Statement of Cash Flows (Un-audited)**  
For the third quarter ended 31st March , 2022. ( Figure in Taka "000")

	March,31 2022	March,31 2021
<b>A. Cash flows from Operating Activities:</b>		
Cash Received from Customers	275,996	296,008
Cash Paid to Suppliers & Employees	(229,604)	(238,969)
<b>Cash generated from Operations:</b>	<b>46,392</b>	<b>57,039</b>
Income Tax Paid	(8,147)	(2,632)
<b>Net Cash from Operating Activities</b>	<b>38,244</b>	<b>54,407</b>
<b>B. Cash flows from Investing Activities</b>		
Purchase of Property, Plant & Equipment	(29,927)	(68,813)
Proceeds from sale of Fixed Assets	-	406
Bank Interest	638	384
FDR interest	2,100	2,675
<b>Net Cash used in Investing Activities</b>	<b>(27,189)</b>	<b>(65,348)</b>
<b>C. Cash flows from Financing Activities</b>		
Dividend paid	(18,875)	-
Bank Loan Received	-	55,000
Unclaimed Dividend	(8,121)	924
<b>Net Cash Used in Financing Activities</b>	<b>(26,996)</b>	<b>55,924</b>
<b>D. Net Cash Inflows / (outflows)</b>	<b>(15,941)</b>	<b>44,983</b>
<b>E. Opening Cash &amp; Bank Balance</b>	<b>67,308</b>	<b>26,692</b>
<b>F. Closing Cash &amp; Bank Balance</b>	<b>51,367</b>	<b>71,675</b>

**Additional information as per listing regulation:**

Particulars	March,31 2022	June,30 2021
Net Assets Value per Share (NAV)	51.73	51.46
Earning Per Share(EPS)	1.27	1.58
Net Operating Cash Flow Per Share(NOCFPS)	2.03	2.88

**Reasons of deviation in financial parameters:**

**Operating results:**

Operating result in the reporting period has been decreased due to the following reasons, compared to previous corresponding period:

- Revenue has been decreased by Tk. 2.51 Crore.
- Administrative expenses has been increased from 45.31% to 47.47% of revenue.

Net operating cash flow per share (NOCFPS) decreased from Tk. 2.88 in March 2021 to Tk.2.03 in March 2022 due to the following reasons:

- Cash Received from Customers has been decreased by Tk. 2.00 Crore.
- Income Tax Paid has been increased by Tk.55.15 lac.

  
CFO

  
Company Secretary

  
Managing Director

  
Director

  
Chairman

"The details of the published third quarter financial statements can be available in the web-site of the company. The address of the web-site is [www.samoritahospital.org](http://www.samoritahospital.org) "

**Samorita Hospital Limited**  
Selected Notes to the Financial Statements(Un-audited)  
For the third quarter ended 31st March , 2022.

**1.00 Legal status and nature of the Company-Disclosure under IAS-1 "Presentation of Financial Statements".**

**1.01 Company Profile**

Samorita Hospital Limited started its business from 01 February 1984 under the name and style as "M/s. Samorita Nursing Home". Then it was a partnership concern and 14 October 1985 it was converted into a Private Limited Company. Subsequently its name and style was changed and renamed as Samorita Hospital (Pvt.) Limited on 17 January 1990. Again on 23 June 1996 it was converted into a Public Limited Company under the name and style as "Samorita Hospital Limited".

The company went for public issue of share in 1996 and its shares are listed with the Stock Exchanges of Bangladesh.

**1.02 Basis of preparation of Financial Statements:**

These interim Financial Statements should be read in conjunction with the financial statements for the year ended 30th June, 2021 as they provide an update to previously reported information.

The Accounting Policies used are consistent with those in the Annual Financial Statements. The Financial Statements have been prepared in accordance with the applicable International Financial Reporting Standards (IFRS). The Presentation of the interim Financial Statements is consistent with the Annual Financial Statements.

**1.03 Investment in associate Company:**

The Company's investment in associate company is accounted for in the financial statements using the Equity Method in accordance with IAS-28 "Investment in Associates".

**2.00 Specific Accounting Policies selected and applied for Significant Transactions and Events:**

**2.01 Accounting Convention (Measurement IASs)**

The financial statements have been prepared on a going concern basis under the historical cost convention in accordance with International Financial Reporting Standards (IFRSs) therefore, do not take into consideration the effect of inflation.

**2.02 Statement of compliance**

The financial statements have been prepared in accordance with the applicable International Financial Reporting Standards (IFRSs), and The Companies Act 1994 and Securities & Exchange Rules 1987.

**2.03 Reporting Currency and Level of Precision**

The financial statements are presented in Bangladeshi Taka (BDT) which is the functional currency of the company. The amounts in these financial statements have been rounded off to the nearest integer.

**2.04 Risk and Uncertainties for use of estimates in preparation of Financial Statements**

The preparation of Financial Statements in conformity with the International Financial Reporting Standards requires management to make estimates and assumptions that affects the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and revenue and expenses during the period reported. Actual result could differ from those estimates. Estimates are used for accounting certain items such as long term contract, provision for doubtful contracts, depreciation and amortization, Tax reserve and contingencies.

**2.05 Reporting Period**

The company's accounting year is July-June and this financial statements are prepared covering the period of nine month from 01 July 2021 to 31 March 2022.

**2.06 Comparative Information**

Comparative information has been disclosed in respect of the period in accordance with IAS-1: Presentation of Financial Statements, for all numeric information in the financial statements and also the narrative and descriptive information where it is relevant for understanding of the current period's financial statements.

**2.07 Recognition of Property, Plant & Equipment and Depreciation**

Property, plant & equipment are recognized if it is probable that future economic benefits associated with the assets will flow to the company and the cost of the assets can be reliably measured. All fixed assets are stated at cost or revaluation less accumulated depreciation as per IAS-16 "Property, Plant and Equipment". No depreciation is charged on land and land development. The cost of acquisition of an asset comprises its purchase price and any directly attributable cost of bringing the asset to its working condition for its intended use inclusive of inward freight, duties and non-refundable taxes. The cost and accumulated depreciation of depreciable assets retired or otherwise disposed of are subject to elimination from the assets and accumulated depreciation and any gain or loss on such disposal will reflect in operations for the period.

**2.08 Inventories**

Inventories comprise various Medicine, Material for Pathology, X-Ray, OT, Cleaning Materials, Linens, Printing and Stationery, Materials for ECG and USG. They are stated at the lower of cost and net realizable value in accordance with IAS -2 "Inventories" after making due allowances for any obsolete or slow moving items.

## **2.09 Financial Instruments**

### **Financial Assets**

#### **Accounts Receivable**

Accounts receivables are recognized and stated at original invoiced amounts and carried at anticipated realizable values.

#### **Cash and Cash Equivalent**

It includes cash in hand and cash at bank which were held and available for use by the company without any restriction and there was insignificant risk of change in value of these current assets.

## **2.10 Creditors and Accrued Expenses**

Liabilities are recognized for amounts to be paid in future for goods and services received, whether or not billed by the supplier.

## **2.11 Taxation**

Income tax expenses comprise current and deferred taxes. Income taxes are recognized in statement of profit or loss and other comprehensive income except to the extent that relates to items recognized directly in equity or in other comprehensive income. The Company is a publicly traded Company. As per the Income Tax Ordinance, 1984, provision for Tax has been made at the existing rate of 22.50% in respect of business income.

### **Current Tax**

Provision for current income tax has been made as per prescribed rate in the Finance Act, 2019 on the accounting profit made by the company after considering some of the add backs to income and disallowances of expenditure as per income tax laws in compliance with IAS-12: "Income Taxes".

### **Deferred Tax**

Deferred tax liabilities are the amount of income taxes payable in future periods in respect of taxable temporary differences. Deferred tax assets are the amount of income taxes recoverable in future periods in respect of deductible temporary differences. Deferred tax assets and liabilities are recognized for the future tax consequences of timing differences arising between the carrying values of assets, liabilities, income and expenditure and their respective tax bases. Deferred tax assets and liabilities are measured using tax rates and tax laws that have been enacted or substantially enacted at the balance sheet date. The impact on the account of changes in the deferred tax assets and liabilities has also been recognized in the statement of comprehensive income as per IAS-12: "Income Taxes".

## **2.12 Revenue Recognition**

In accordance with the provisions of the IFRS-15: "Revenue from Contracts with Customers"; revenue from contracts with customers represents the amount that reflects the considerations to which entity expects to be entitled in exchange for goods supplied and service provided to customers during the year. Revenue from contracts with customers is recognized in the statement of profit or loss and other comprehensive income when the performance obligation (supply of promised goods and services) is satisfied. Performance obligation is satisfied at a point in time when customer obtains the control of goods and services. Revenue has been recognized at the time of invoice made for the services rendered by the company.

### **Interest income**

The interest income is recognized on accrual basis as agreed terms and conditions with the banks.

### **Non operating income**

Non operating income are recognized at the time of receive of money from other purpose than the normal course of business of the Company.

## **2.13 Earnings Per Share (EPS)**

The Company calculates Earnings Per Share (EPS) in accordance with IAS -33 "Earnings Per Share", which has been shown on the face of the statement of comprehensive income. This has been calculated by dividing the basic earnings by the number of ordinary shares outstanding during the year.

## **2.14 Statement of Cash Flows**

Statement of Cash Flows is prepared principally in accordance with IAS -7 "Statement of Cash Flows" and the cash flow from the operating activities have been presented under the direct method as prescribed by the Securities and Exchange Rules 1987 and considering the provision of Paragraph 19 of IAS -7 which provides that enterprise are encouraged to report "Cash Flow from the Operating Activities using the direct Method".

## **2.15 Additional information on Financial Statements:**

### **Compliance with International Financial Reporting Standards (IFRSs)**

The financial statements have been prepared in compliance with requirements of IFRSs adopted by the Institute of Chartered Accountants of Bangladesh (ICAB).

## **2.16 Foreign Exchange Earned and Payment**

During the period the Company has not earned or made payment any amount of foreign currency.

## 2.17 Provisions, Contingent Liabilities and Contingent Assets (IAS-37)

There are certain pending tax claims made against the Company, which will be settled through the legal process in due course. These are being vigorously defended by the company. The management has not considered it necessary at the reporting date to make provisions in the financial statements in respect of any of these claims.

Accounting Year	Assessment Year	Tax Declared	Assessment by Tribunal	Tax paid	Tax Liability/ Claimed Amount	Present Status
2012-2013	2013-2014	13,623,217	12,843,912	13,723,217	(879,305)	Case is Pending at High court
2013-2014	2014-2015	11,669,566	15,739,609	12,879,566	2,860,043	Case is Pending at High court
2014-2015	2015-2016	11,473,176	12,616,428	11,773,176	843,252	Case is Pending at High court
2015-2016	2016-2017	10,372,742	12,904,058	11,482,742	1,421,316	Case is Pending at High court
2016-2017	2017-2018	13,918,465	14,450,494	14,433,465	17,029	Case is Pending at High court
2017-2018	2018-2019	8,675,427	8,893,836	12,247,897	(3,354,061)	As per Assessment order
2018-2019	2019-2020	11,453,108	-	11,453,108	-	Return Submitted but Assessment not yet done
2019-2020	2020-2021	3,678,790	-	8,929,484	(5,250,694)	Return Submitted but Assessment not yet done
2020-2021	2021-2022	13,632,068	-	7,746,630	5,885,439	Return Submitted but Assessment not yet done
<b>Total</b>		<b>98,496,559</b>	<b>77,448,337</b>	<b>104,669,285</b>	<b>1,543,019</b>	

## 2.18 Impairment of Assets (IAS-36)

No facts and circumstances indicate that the company's assets may be impaired. Hence, no evaluation of recoverability of assets was performed.

## 2.19 Employee Benefits (IAS-19)

The Company provides short term employee benefits to its eligible employees in the form of incentive which charged as revenue expenditure in the period to which the incentive relates.

## 2.20 Workers' Profit Participation and Welfare Fund:

The Company recognizes a provision for Workers' Profit Participation Fund @ 5% of net profit before Taxes in accordance with Bangladesh Labour Law 2006.

## 3. Property, Plant & Equipment:

### Cost/Revaluation:

Land	760,746	760,246
Building	215,908	213,309
Equipments	160,239	156,077
Furniture & Fixture	25,189	24,819
Lift	13,870	13,870
Generator	7,630	7,630
Medical Oxygen System	28,996	28,387
Others	44,451	44,140
	<b>1,257,029</b>	<b>1,248,478</b>
Less: Accumulated Depreciation	318,077	303,188
Written Down Value	<b>938,952</b>	<b>945,290</b>
Add: Work in Progress -Building	17,963	-
	<b>956,915</b>	<b>945,290</b>

## 4. Investment in Associate:

Opening Balance	5,794	5,865
Share of income / (loss) of Associate (note.23)	28	(71)
	<b>5,822</b>	<b>5,794</b>

Share of income of Associate has been shown on the basis of unaudited report of the Imaging services Ltd. (Associate company) for the nine months ended March 31, 2022 in accordance with IAS-28.

	As at March, 31 2022	As at June, 30 2021
Figure in Taka"000"		
<b>5. Inventories:</b>		
Medical Services	3,723	3,744
Diagnostics	2,305	1,821
Pharmacy	14,702	14,887
	<u>20,730</u>	<u>20,452</u>
<b>6. Accounts Receivable:</b>		
Receivable from Indoor Patient	7,044	6,076
Receivable from Outdoor Patient	359	200
Receivable from Institution	4,579	3,575
Rent Receivable	176	151
Receivable from FDR Interest	420	428
	<u>12,578</u>	<u>10,430</u>
<b>7. Advance, Deposits &amp; Prepayments :</b>		
Advance for Work & others	5,973	5,080
Advance for Capital Item	15,840	12,426
Security Money & Deposit	1,973	1,973
Prepayments	843	310
	<u>24,629</u>	<u>19,789</u>
<b>8. Advance Income Tax</b>		
Opening Balance	17,743	15,663
Add: Paid during the year	6,138	5,759
	<u>23,881</u>	<u>21,422</u>
Less: Adjusted during the year	5,811	3,679
<b>Closing Balance</b>	<u>18,070</u>	<u>17,743</u>
<b>9. Short-term investment in FDR</b>		
Union Bank FDR	40,000	40,000
<b>10. Cash &amp; Cash Equivalents :</b>		
Cash in hand	997	1,619
Cash at bank	50,370	65,689
	<u>51,367</u>	<u>67,308</u>
<b>11. Issued, Subscribed and Paid up Capital:</b>		
1,88,75,236 shares @ Tk. 10.00 each	188,752	188,752
<b>12. Retained Earnings</b>		
Opening Balance	145,705	103,617
Less: Transfer to Dividend	18,875	-
	<u>126,830</u>	<u>103,617</u>
Less: Transferred to Dividend Equalisation Fund	2,104	-
	<u>124,726</u>	<u>103,617</u>
Add: Total Comprehensive Income for the year	24,063	42,088
<b>Retained Earnings</b>	<u>148,789</u>	<u>145,705</u>
<b>13. Revaluation Reserve</b>		
Opening Balance	636,826	636,826
Less: Adjustment	-	-
	<u>636,826</u>	<u>636,826</u>
Add: Transferred from deferred tax liabilities (Note: 13.01)	-	-
	<u>636,826</u>	<u>636,826</u>
<b>13.01. Movement in deferred Tax Liability</b>		
Closing balance	27,792	27,792
Opening balance	27,792	27,792
	<u>-</u>	<u>-</u>
<b>14. Dividend Equalisation Fund:</b>		
As per decision of 188th meeting of the Board of Directors held on July 18, 2020 an amount of Tk.2,104,419 equivalent to 5% of net profit of the year 2020-21 has been transferred to Dividend Equalisation fund.		
<b>15. Deferred Tax Liabilities</b>		
Opening Balance	40,433	41,620
Add: Provision made during the year for temporary difference(Note:15.01)	(1,050)	(1,187)
	<u>39,383</u>	<u>40,433</u>
Less: Adjustment during the year	-	-
	<u>39,383</u>	<u>40,433</u>

**15.01. Deferred tax liability is arrived at as follows :**

**A. Property, Plant & Equipments:**

Figure in Taka"000"

	As per Accounting Base(W.D.V)	As per Tax Base(W.D.V)	Temporary Difference Taxable/
Land	274,334	222,817	51,517
Other than Land	96,128	96,128	-
<b>Tax Rate</b>	178,206	126,689	51,517
On Land			0%
On other than Land			22.50%
<b>Deferred Tax Liability</b>			
For Land			-
For other than Land			11,591
<b>Deferred tax liability for normal temporary difference</b>			11,591

**B. Calculation of deferred tax on revaluation of property, plant and equipment:**

Revalued value of Land	694,800	-	694,800
	694,800	-	694,800
<b>Tax Rate</b>			4%
On Land			
<b>Deferred Tax Liability</b>			
For Land			27,792

**Total deferred tax liability (A+B)**

**Deferred tax expenses / (income) :**

**Calculation of deferred tax expenses/ (income) on cost**

	March.31, 2022	March.31, 2021
Closing Balance	11,591	15,108
Less: Opening Balance	12,641	13,828
<b>Deferred tax income accounted for during the Period.</b>	(1,050)	1,280

**16. Long Term Borrowings**

**a. Principle Amount**

Opening Balance	56,504	-
Add: Addition during the year	-	55,000
<b>Less: Repayment</b>	56,504	55,000
<b>Total</b>	56,504	55,000

**b. Interest Amount**

Opening Balance	-	-
Add: Addition during the year	4,001	1,504
<b>Less: Repayment</b>	4,001	1,504
<b>Total</b>	4,001	1,504
<b>Closing Balance</b>	60,505	56,504
Less: Long Term Borrowings (Current Portion) (note 18)	21,060	5,265
<b>Total</b>	39,445	51,239

All fixed and floating assets are mortgaged against long term loan.

**17. Accounts Payable:**

Advance Receipt from Undischarged Patient	3,396	2,476
Advance Receipt from MTB & Others	465	450
Current Liability for Expenses	360	675
Current Liabilities for Supply	7,384	8,597
Workers profit participation fund (note 17.01)	13,685	12,347
<b>Total</b>	25,290	24,545

**17.01. Workers profit participation fund :**

Opening Balance	12,347	9,621
Less: Paid During the year	214	-
<b>Add: Provision made during the year</b>	12,133	9,621
	1,552	2,726
<b>Total</b>	13,685	12,347

	As at March, 31 2021	As at June, 30 2021
Figure in Taka"000"		
<b>18. Long Term Borrowings (Current Portion)</b>		
Opening Balance	5,265	-
Add: Addition during the year	15,795	5,265
	<u>21,060</u>	<u>5,265</u>
Less: Repayment	-	-
Total	<u>21,060</u>	<u>5,265</u>
<b>19. Other Payables</b>		
Suppliers & Others Vat	837	610
Suppliers & Others Tax	1075	506
Managing Directors Salary Tax	159	70
	<u>2,071</u>	<u>1,186</u>
<b>20. Provision &amp; Accruals:</b>		
Utility Bills	789	1,386
Salary & Allowance	7,736	7,940
Bad debt	2,321	-
Others	216	288
	<u>11,062</u>	<u>9,614</u>
<b>21. Liability for Income Tax</b>		
Opening Balance	13,632	3,679
Less: Adjusted during the year (Note-8)	5,811	3,679
	<u>7,821</u>	<u>-</u>
Less: Paid During the Year	2,009	-
	<u>5,812</u>	<u>-</u>
Add: Provision made during the year	8,028	13,632
	<u>13,840</u>	<u>13,632</u>
<b>Liability for short Provision of income tax</b>		
Opening Balance	316	316
Less: Paid during the year	-	-
	<u>316</u>	<u>316</u>
Closing Balance	<u>14,156</u>	<u>13,948</u>
<b>22. Unclaimed Dividend</b>		
Opening Balance	9,293	8,192
Add : Addition during the year	45	1,129
	<u>9,338</u>	<u>9,321</u>
Less: Paid during the year	8,166	28
	<u>1,172</u>	<u>9,293</u>
<b>23. Share of Profit / (loss) of Associate :</b>		
Net profit/ (loss) of Associate company	62	(157)
Share of Profit/ (loss) of Associate company (45% of Tk. 62 )	28	(71)

	March, 31 2022	March, 31 2021
Figure in Taka"000"		
<b>24. Revenue</b>		
Medical Services	120,410	139,265
Diagnostic	67,248	58,423
Pharmacy	86,412	101,502
	<u>274,070</u>	<u>299,190</u>
<b>25. Direct Expenses:</b>		
Medical Services	22,376	26,285
Diagnostic	28,322	25,097
Pharmacy	62,583	72,841
	<u>113,281</u>	<u>124,223</u>

**26. Administrative Expenses:**

	March, 31 2022	March, 31 2021
Salary & Allowance	70,513	76,067
Managing Director's Salary	3,872	3,813
Utility Bills	10,900	11,037
Repair Works	4,146	6,614
Depreciation	14,889	15,257
Printing	1,268	977
Bad debt	2,321	2,444
Others	22,191	19,350
	<b>130,100</b>	<b>135,559</b>

Figure in Taka"000"

**27. Non Operating Income**

Rent Received	2,167	990
FDR Interest	2,092	2,522
Bank Interest	638	384
Referral Income	491	360
Profit/(loss) on sale of Fixed Assets (note-27.01)	-	(72)
Others	490	730
	<b>5,878</b>	<b>4,914</b>

**27.01. Profit/(loss) on sale of Fixed Assets:**

Sales Value	-	406
Less: Written down Value	-	478
	<b>-</b>	<b>(72)</b>

**28. Current year's Tax**

Profit before Tax	31,041	42,034
Add: Investment income (profit) / Loss of Associates	(28)	(61)
Add: (Profit) / Loss on Sale of Fixed Assets	-	72
Add: Depreciation as per Accounting base	14,889	15,257
	<b>45,903</b>	<b>57,301</b>
Less: Depreciation as per Tax base	10,223	13,595
	<b>35,680</b>	<b>43,706</b>
Applicable Tax rate	22.50%	25.00%
	<b>8,028</b>	<b>10,927</b>

**29. Special disclosure as per notification No. BSEC/CMRRCD/2006-158/208/Admin/81 is as under:****a) Detailed break-up of shareholders equity:**

	As at March, 31 2022	As at June, 30 2021
Share Capital (note- a.01)	188,752	188,752
Retained Earnings (note- a.02)	148,789	145,705
Revaluation Reserve (note- a.03)	636,826	636,826
Dividend Equalisation Fund (note-a.04)	2,104	-
<b>Total Equity</b>	<b>976,471</b>	<b>971,283</b>

Figure in Taka"000"

**a.01. Paid-up capital:**

Type of Share	No. of Shares	Face value	Issu Date		
Ordinary Share	6,000	10.00	10/11/1997	60,000	60,000
Bonus Share	600	10.00	23/04/2005	6,000	6,000
Bonus Share	990	10.00	26/01/2010	9,900	9,900
Bonus Share	1,214	10.00	08/02/2012	12,140	12,140
Bonus Share	1,584	10.00	24/01/2013	15,844	15,844
Bonus Share	3,117	10.00	26/01/2014	31,170	31,170
Bonus Share	1,351	10.00	07/01/2015	13,510	13,510
Bonus Share	1,486	10.00	26/12/2016	14,860	14,860
Bonus Share	1,634	10.00	28/12/2017	16,340	16,340
Bonus Share	899	10.00	05/01/2020	8,988	8,988
<b>Total: 1,88,75,236 shares @ Tk. 10.00 each</b>				<b>188,752</b>	<b>188,752</b>

Figure in Taka"000"

**a.02. Retained Earnings**

Opening Balance	145,705	103,617
Less: Dividend	18,875	-
	<b>126,830</b>	<b>103,617</b>
Less: Transferred to Dividend Equalisation Fund	2,104	-
	<b>124,726</b>	<b>103,617</b>
Add: Total Comprehensive Income for the year	24,063	42,088
<b>Retained Earnings</b>	<b>148,789</b>	<b>145,705</b>

**a.03, Revaluation Reserve**

	As at March, 31 2022	As at June, 30 2021
Opening Balance	636,826	636,826
Less: Adjustment	-	-
	636,826	636,826
Add: Transferred from deferred tax liabilities (Note: a.03a)	-	-
	<b>636,826</b>	<b>636,826</b>
<b>a.03a, Movement in deferred Tax Liability:</b>		
Closing balance	27,792	27,792
Opening balance	27,792	27,792
	-	-

Figure in Taka"000"

**a.04, Dividend Equalisation Fund:**

As per decision of 188th meeting of the Board of Directors held on July 18, 2020 an amount of Tk.2,104,419 equivalent to 5% of net profit of the year 2020-21 has been transferred to Dividend Equalisation fund.

**b) Net Asset Value Per Share (NAV)**

Total Assets	1,130,111	1,126,806
Less Total liabilities :	153,640	155,523
Non Current Liabilities	78,828	91,672
Current Liabilities	74,812	63,851
Net Assets:	976,472	971,283
Number of outstanding shares at the year end	18,875	18,875
Net Asset Value Per Share (NAV)	<b>51.73</b>	<b>51.46</b>

**c) Basic and diluted Earnings Per Share:****Basic Earning Per Share:**

	March, 31 2022	March, 31 2021
Profit Attributable to ordinary shareholders	24,063	29,827
Number of outstanding shares at the year end	18,875	18,875
Basic Earning per Share (EPS)	<b>1.27</b>	<b>1.58</b>

Figure in Taka"000"

**Diluted Earning Per Share:**

Diluted EPS is determined by adjusting the Profit or loss attributable to ordinary shareholders and the weighted average number of ordinary shares outstanding, for the effects of all dilutive potential ordinary shares. However, dilution of EPS is not applicable for these financial statements as there was no potential dilutive ordinary share during the relevant period.

**d) Net operating cash flows per share (NOCFPS)**

Net Cash from Operating Activities	38,244	54,407
Number of outstanding shares at the year end	18,875	18,875
Net operating cash flows per share (NOCFPS)	<b>2.03</b>	<b>2.88</b>

**e) Reconciliation of Net profit with Cash Flows from Operating Activities**

For the third quarter ended 31st March , 2022.

Particulars	March, 31 2022	March, 31 2021
Figure in Taka"000"		
Profit Before Tax	31,041	42,034
Depreciation	14,889	15,257
Bad debt	2,321	2,444
(Gain) / Loss on Disposal	-	72
FDR Interest	(2,092)	(2,522)
Bank Interest	(638)	(384)
Investment Income (Share of (Profit) /Loss of Associates)	(28)	(61)
Financial Charges	4,001	248
(Increase)/Decrease in Inventories	(278)	2,109
(Increase)/Decrease in Trade and other receivable	(2,156)	(7,335)
(Increase)/Decrease in Advance, Deposits & Prepayment	(1,426)	755
Increase/(Decrease) in Trade Payable	(593)	(175)
Increase/(Decrease) in other Payable	885	1,275
Increase/(Decrease) in Provision & accruals	(874)	1,221
Increase/(Decrease) in WPPF	1,338	2,102
Cash Flows from operation	<b>46,391</b>	<b>57,039</b>
Tax Paid	(8,147)	(2,632)
	<b>38,244</b>	<b>54,407</b>

**30. Related Party Disclosures (IAS-24):**


as on 31st March 2022 ( Figure in Taka "000")

SL.No	Particulars	Nature of Relation	Basis of transactions	Total Transaction Value	Outstanding
1.00	Nurse Hostel	Mrs. Latifa Haroon, W/O Dr.A B M Haroon	Rent paid as per contract	1,477	
2.00	The Imaging Services Ltd.	Associate company	Rent received as per contract	720	80
3.00	Purabi General Insurance Company Limited	Common director	Insurance Premium paid as per contract	196	
4.00	Sandhani Life Insurance Company Limited	Common director	Life Insurance Premium paid as per contracts	18	
5.00	M.H. Samorita Hospital & Medical College	Common director	Pathology Test as per negotiation	1,278	1,278

  
C F O

  
Company Secretary

  
Managing Director

  
Director

  
Chairman